Moderna and Merck have reported promising mid-stage trial data for their experimental cancer vaccine when used in combination with Merck’s Keytruda therapy. The vaccine, expected to launch in some countries as early as 2025, demonstrated a 49% reduction in the risk of death or recurrence of the most deadly form of skin cancer, melanoma, after… Continue reading Moderna, Merck vaccine with Keytruda cuts risk of deadly skin cancer returning in half, data says

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) is pleased to introduce its K-beauty online store(https://tonymoly.ca/) featuring the acclaimed TonyMoly brand. This digital platform offers a selective range of TonyMoly’s K-beauty products, such as makeup and skincare products, catering to the burgeoning demand for K-beauty across Canada. Dedicated to TonyMoly’s product… Continue reading Justera Health (CSE:VTAL) Introduces K-Beauty Online Store

Pfizer’s shares experienced a decline after the pharmaceutical giant provided a 2024 revenue and profit forecast below Wall Street expectations, citing weak demand for its once highly profitable Covid products. The company also increased the target for its cost-cutting initiative by an additional $500 million, now totaling $4 billion. Pfizer’s projection for 2024 revenue is… Continue reading Pfizer shares fall as 2024 revenue and profit forecast disappoints

Google has introduced MedLM, a suite of healthcare-specific artificial intelligence (AI) models designed to assist clinicians and researchers in complex studies and doctor-patient interaction summaries. This move reflects Google’s ongoing efforts to monetize AI tools in the healthcare industry amid fierce competition from rivals like Amazon and Microsoft. The MedLM suite comprises large and medium-sized… Continue reading Google is rolling out new AI models for health care. Here’s how doctors are using them

Patients who took Eli Lilly’s weight loss drug Zepbound regained approximately half the weight they had lost after stopping the treatment for a year, according to data released in the research journal JAMA. The study, funded by Eli Lilly, spanned 88 weeks and included 670 obese patients without diabetes. Initial results, released in July, indicated… Continue reading Patients regain weight after stopping Eli Lilly’s Zepbound, study says

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share a significant development. The company has unveiled a noteworthy partnership with a Nasdaq-listed biopharmaceutical company, with a shared objective of forging precise and efficient manufacturing pathways for advanced intermediates and high-value active pharmaceutical ingredients (APIs). Savile provided insights into this partnership’s progress,… Continue reading Willow Bioscience plans to advance development program with Nasdaq-listed company

In Las Vegas, Lazaro Hernandez, a flamboyant poker player, was found to be overseeing a nationwide $230 million scheme to counterfeit prescription medications, focusing on lifesaving HIV drugs. The operation involved altering pill bottles for medications like Biktarvy and Descovy, replacing them with antipsychotic drugs like Seroquel. Hernandez, based in south Florida, funded his counterfeiting… Continue reading Fraud in a bottle: How Big Pharma takes on criminals who make millions off counterfeit drugs

Healthcare giant Cigna’s stock surged nearly 14% following reports that it has abandoned plans to acquire rival Humana due to disagreements on price. The proposed deal, valued at over $140 billion, would have created a significant healthcare conglomerate, attracting potential antitrust scrutiny. Cigna also announced a $10 billion share buyback plan, bringing the total planned… Continue reading Cigna shares jump on reports of abandoned Humana buyout, plans for $10 billion stock buyback

The U.S. Food and Drug Administration (FDA) has granted approval for Casgevy, marking the first gene-editing treatment for sickle cell disease. Developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy utilizes the revolutionary CRISPR technology to edit human DNA, showcasing a significant scientific breakthrough. This approval follows the nod from U.K. regulators received last month,… Continue reading U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease

The United States Food and Drug Administration (FDA) has completed its filing review and has accepted Alpha Cognition Inc.’s new drug application (NDA) for ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s disease. The NDA has been granted a Prescription Drug User Fee Act (PDUFA) goal… Continue reading ALPHA COGNITION ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ALPHA-1062 FOR MILD-TO-MODERATE ALZHEIMER’S DISEASE

At 19, Joe Tsogbe underwent his first hip replacement due to sickle cell disease, an inherited blood disorder causing excruciating pain. By his 30s, he averaged over a dozen hospitalizations annually. Sickle cell disease results from a genetic mutation causing red blood cells to form half moons and obstruct blood vessels. It primarily affects about… Continue reading U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients

The Biden administration has intensified its efforts to curb high drug prices and promote pharmaceutical competition by asserting its authority to seize patents for certain expensive medications. The administration unveiled a framework delineating the factors federal agencies should consider when deciding to use march-in rights, a controversial policy allowing the breaking of patents for drugs… Continue reading Biden administration asserts power to seize drug patents in move to slash high prices